Literature DB >> 32173528

Cancer cell selective probe by mimicking EGCG.

Motofumi Kumazoe1, Shun Hiroi1, Yousuke Tanimoto2, Jyunichi Miyakawa2, Maasa Yamanouchi2, Yumi Suemasu1, Ren Yoshitomi1, Motoki Murata1, Yoshinori Fujimura1, Takashi Takahashi3, Hiroshi Tanaka2, Hirofumi Tachibana4.   

Abstract

Targeting proteins that are overexpressed in cancer cells is the major strategy of molecular imaging and drug delivery systems. The 67-kDa laminin receptor (67LR), also known as oncofetal antigen, is overexpressed in several types of cancer, including melanoma, multiple myeloma, cervical cancer and bile duct carcinoma. 67LR is involved in tumour growth, tumour metastasis and drug resistance. Green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG) directly binds to cell-surface 67LR and induces apoptosis through the protein kinase B (Akt)/endothelial nitric oxide synthase/nitric oxide/cyclic GMP (cGMP) axis. Here we report the optimum hydroxyl group for the utilization of EGCG as a novel fluorescent EGCG-mimic imaging probe based on 67LR agonist characters, including Akt activation and inhibitory effect on viable cell number in cancer cells. 67LR specific targeting is unambiguously confirmed with the use of a non-labelled EGCG competitive assay and 67LR knockdown. Importantly, this probe strongly binds to multiple myeloma cells compared with its binding to normal cells.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  67LR; Cancer; EGCG; Fluorescent probe; Imaging

Mesh:

Substances:

Year:  2020        PMID: 32173528     DOI: 10.1016/j.bbrc.2020.03.021

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Src Mediates Epigallocatechin-3-O-Gallate-Elicited Acid Sphingomyelinase Activation.

Authors:  Motofumi Kumazoe; Mai Kadomatsu; Jaehoon Bae; Yushi Otsuka; Yoshinori Fujimura; Hirofumi Tachibana
Journal:  Molecules       Date:  2020-11-23       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.